The application of CDK1 inhibitors has been reported to improve the efficacy of the chemotherapeutic drug sorafenib targeting tumor stem cells in the treatment of hepatocellular carcinoma, anti-CDK1 combination chemotherapy significantly inhibits tumor growth in hepatocellular carcinoma, while being able to overcome resistance to sorafenib [59]. Here, CDK1 is linked to neoplasm.